Engineering the Future of Periodontal Therapeutics
The New Standard of Care
For over two decades, the standard of care for locally administered subgingival antibiotics has remained stagnant. Legacy delivery systems are plagued by mechanical flaws—relying on crushable tips and heavy metal handles that cause patient discomfort, unpredictable dosing, and severe clinical workflow bottlenecks.
​
At PharmaPhD, we have engineered a paradigm shift. By combining an advanced, atraumatic delivery architecture with an industry-leading, high-purity microencapsulation formulation, our technology systematically eliminates the clinical risks of legacy treatments.
​
We have adapted this core technology into two distinct, pre-commercial candidate products:
01
PerioER™
Advanced Human Clinical Periodontal Therapy
Designed specifically for the modern Dental Service Organization (DSO) and private practice, PerioER™ is a next-generation combination product candidate.
It replaces the heavy metal handles of legacy systems with a fully disposable, single-use architecture.​​
02
Periocin™
Veterinary Periodontal Innovation
Periodontal disease is the number one diagnosed condition in adult dogs and cats, directly impacting their systemic health and lifespan.
Periocin™ adapts PharmaPhD’s proprietary micro-particle delivery system specifically for veterinary dentistry.​​
Strategic Partnerships & Acquisitions
​
PharmaPhD is actively expanding the commercial footprint of our proprietary delivery technologies. PerioER™ and Periocin™ represent commercial-ready assets supported by a robust intellectual property portfolio, scalable domestic manufacturing, and a thoroughly optimized regulatory strategy.
​
For pharmaceutical organizations, private equity partners, and medical device acquirers seeking premium assets in the multibillion-dollar dental market, we invite you to connect with our executive team. Detailed engineering, financial, and regulatory data is available under a Non-Disclosure Agreement (NDA).
Regulatory Notice:
​​
PerioER™ and Periocin™ are investigational, pre-commercial candidate products. They have not been approved by the FDA (CDER/CVM) and are not available for commercial sale. Information presented herein contains forward-looking statements. For complete information, please view our Full Legal Disclaimers